Effects of IV-Administered Ca-DTPA and Zn-DTPA To Treat Patients With Gadolinium Deposition Disease
Condition(s):Headache; Cognitive Disturbance; Skin Hyperpigmentation; ArthralgiaLast Updated:April 6, 2018Terminated
Hide Studies Not Open or Pending
Condition(s):Headache; Cognitive Disturbance; Skin Hyperpigmentation; ArthralgiaLast Updated:April 6, 2018Terminated
Condition(s):Renal Insufficiency, Chronic; Kidney DiseasesLast Updated:May 18, 2018Terminated
Condition(s):Kidney DiseaseLast Updated:January 11, 2019Completed
Condition(s):Gadolinium Deposition DiseaseLast Updated:February 5, 2024Active, not recruiting
Condition(s):Heavy Metal ToxicityLast Updated:August 29, 2017Withdrawn
Condition(s):Acute Myeloid Leukemia; Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Chronic Myelogenous Leukemia, BCR-ABL1 Positive; High Risk Myelodysplastic Syndrome; Myelodysplastic Syndrome; Myelodysplastic/Myeloproliferative Neoplasm; Myeloproliferative Neoplasm; Recurrent Acute Myeloid Leukemia; Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Recurrent Myelodysplastic Syndrome; Recurrent Myelodysplastic/Myeloproliferative Neoplasm; Refractory Acute Myeloid Leukemia; Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Refractory Myelodysplastic Syndrome; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndrome; Very High Risk Myelodysplastic SyndromeLast Updated:September 21, 2023Recruiting
Condition(s):Lymphoma; Radiation ToxicityLast Updated:June 20, 2013Completed
Condition(s):Hodgkin’s Disease; Lymphoma, Non-HodgkinLast Updated:December 7, 2015Completed
Condition(s):Critical Limb Ischemia; DiabetesLast Updated:February 28, 2024Recruiting
Condition(s):Reversible PulpitisLast Updated:December 8, 2023Active, not recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.